Valuation: Epigral Limited

Market Cap 44.7B 464M 412M 385M 349M 659M 664M 4.63B 1.8B 22.8B 1.74B 1.7B 73.31B P/E 2027 *
12.9x
P/E 2028 * 10.2x
Enterprise Value 50.62B 525M 466M 436M 395M 747M 752M 5.24B 2.04B 25.82B 1.97B 1.93B 83.02B EV / Sales 2027 *
1.64x
EV / Sales 2028 * 1.35x
Free-Float
31.14%
Yield 2027 *
0.53%
Yield 2028 * 0.53%
1 day+1.96%
1 week+0.04%
Current month+2.29%
1 month-14.88%
3 months+1.46%
6 months+17.50%
Current year-14.90%
1 week 975.7
Extreme 975.7
1,061.05
1 month 975.7
Extreme 975.7
1,230.05
Current year 806.2
Extreme 806.2
1,401.35
1 year 806.2
Extreme 806.2
1,739.6
3 years 806.2
Extreme 806.2
2,408.35
5 years 651.05
Extreme 651.05
2,408.35
10 years 386.35
Extreme 386.35
2,408.35
Manager TitleAgeSince
Chief Executive Officer 41 -
Director of Finance/CFO - 2025-11-09
Compliance Officer - 2024-04-21
Director TitleAgeSince
Director/Board Member 75 2017-05-17
Director/Board Member 43 2016-10-04
Director/Board Member 41 2017-05-17
Change 5-day change 1-year change 3-year change Capi.($)
+1.96%+0.04% - - 456M
+1.57%+3.79%+4.98%+32.47% 222B
-0.97%+0.52%+8.35%+30.63% 122B
+0.85%-3.49%-7.34%+26.58% 76.85B
+2.45%+23.11%+660.05%+352.86% 71.44B
+0.55%+0.81%+3.51%+0.41% 62.23B
-0.77%-1.77%-24.35%-43.74% 37.56B
+1.83%-0.72%+3.48%-21.99% 32.17B
+0.22%+0.04%+26.18%+57.06% 24.36B
+2.46%+0.17%+2.82%-24.39% 23.56B
Average +1.06%+0.72%+75.30%+45.54% 74.71B
Weighted average by Cap. +1.11%+1.74%+72.63%+54.57%

Financials

2027 *2028 *
Net sales 30.88B 320M 284M 266M 241M 455M 459M 3.2B 1.24B 15.75B 1.2B 1.18B 50.63B 37.28B 387M 343M 321M 291M 550M 554M 3.86B 1.5B 19.02B 1.45B 1.42B 61.13B
Net income 3.47B 35.95M 31.91M 29.86M 27.07M 51.12M 51.49M 359M 140M 1.77B 135M 132M 5.68B 4.4B 45.61M 40.49M 37.89M 34.34M 64.86M 65.33M 455M 177M 2.24B 171M 168M 7.21B
Net Debt 5.92B 61.38M 54.48M 50.99M 46.21M 87.28M 87.91M 612M 238M 3.02B 230M 225M 9.7B 5.49B 56.94M 50.54M 47.3M 42.87M 80.96M 81.55M 568M 221M 2.8B 214M 209M 9B
Projected Income Statement - Annual - Epigral Limited
Logo Epigral Limited
Epigral Limited is an India-based manufacturer of essential chemicals. The Company is engaged in the manufacturing and selling of chemicals, including derivatives and specialty chemicals. It operates under two businesses, Chlor-Alkali and Derivatives and Speciality chemicals, which relate to the manufacturing of Chlor-Alkali & its Derivatives. Chlor-Alkali is an industrial process that offers Sodium Hypochlorite, Hydrogen Gas, Caustic Soda Lye, Caustic Soda Flakes, and Liquid Chlorine. The Company offers a diverse portfolio of products, including chlorinated polyvinyl chloride (CPVC) Resin, CPVC Compound, Chlorotoluenes Value Chain, Epichlorohydrin, Chloromethanes, Hydrogen Peroxide, Caustic Soda, Chlorine, Hydrogen, and Caustic Potash. The Company caters to a range of industries such as refineries, paper and pulp, fluoropolymers, soaps & detergents, textiles, dyes & pigment, pharmaceuticals, agrochemicals, paints and coating, refrigerant gas, electronics, water treatment, and others.
Employees
1,135
Date Price Change Volume
26-10-06 ₹1,037.60 +1.96% 2,402
26-10-05 ₹1,017.65 +3.48% 4,249
26-10-01 ₹983.40 -3.06% 3,995
26-09-30 ₹1,014.40 -0.28% 1,587
26-09-29 ₹1,017.25 -1.92% 950
Trader
Investor
Global
Quality
ESG MSCI
-
Ratings Surperformance© - Epigral Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1,036.20INR
Average target price
1,728.00INR
Spread / Average Target
+66.76%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Epigral Limited